📗 Cite This Artifact
Alzheimer's Disease Neuroinflammation Companies
Overview
Overview
This category page covers biotechnology and pharmaceutical companies developing therapies that target neuroinflammation in Alzheimer's disease. Neuroinflammation is increasingly recognized as a central driver of neurodegenerative processes, and multiple therapeutic approaches are under development targeting different aspects of the inflammatory cascade.
The main mechanisms being targeted include:
- NLRP3 inflammasome inhibition
- TREM2 modulation on microglia
- TNF-alpha inhibition
- Complement system inhibition
- Microglia modulation
Key Companies
NLRP3 Inflammasome Inhibitors
Nodthera Ltd.
- Focus: NLRP3 inflammasome inhibition
- Lead Candidate: NT-0796
- Indication: Alzheimer's disease
- Stage: Phase 1/2
- Mechanism: Brain-penetrant NLRP3 small molecule inhibitor
- Notes: First-in-class oral therapy targeting neuroinflammation at its source[@nodthera_corp][@nlrp3_review]
Olatec Therapeutics
- Focus: NLRP3 inflammasome inhibition
- Lead Candidate: Dapansutrile (OLT1177)
- Indication: Alzheimer's disease
- Stage: Phase 2
- Mechanism: Oral NLRP3 inhibitor
- Notes: Established safety profile in inflammatory conditions
TNF-Alpha Inhibitors
INmune Bio, Inc.
- Focus: Selective soluble TNF-alpha inhibition
- Lead Candidate: XPro1595
- Indication: Alzheimer's disease (MCI)
- Stage: Phase 2
- Mechanism: Dominant-negative inhibitor of soluble TNFα (preserves membrane-bound TNF)
- Trial ID: NCT05318937
- Notes: Targets neuroinflammation without compromising immune surveillance[@inmune_corp]
TREM2 Targeting
Alector, Inc.
- Focus: TREM2 agonism and progranulin modulation
- Lead Candidates: AL002 (TREM2 agonist), AL101 (progranulin)
- Indication: Alzheimer's disease
- Stage: Phase 2
- Mechanism:
- AL002: TREM2 agonist with Alector Brain Carrier (ABC) platform
- AL101: Progranulin antibody to increase progranulin levels
- Partners: Roche (AL002), GSK (AL101)
- Notes: Pioneer in immuno-neurology approach, targeting microglia dysfunction[@alector_corp][@trem2_review]
Vigil Neuroscience
- Focus: TREM2 agonism
- Lead Candidate: VIG-100
- Indication: Alzheimer's disease
- Stage: Phase 1
- Mechanism: TREM2 activating antibody
- Notes: Focused specifically on TREM2 target[@vigil_corp]
Denali Therapeutics
- Focus: TREM2 and lysosomal function
- Lead Candidates: DNL919 (TREM2 agonist), DNL593 (progranulin modulator)
- Indication: Alzheimer's disease, Parkinson's disease
- Stage: Phase 1
- Mechanism: Engineered antibodies with Brain Transport Vehicle (BTV) delivery platform
- Notes: Strong foundation in lysosomal biology and neurodegenerative disease[@denali_corp]
Complement Inhibitors
Annexon Biosciences
- Focus: C1q inhibition (classical complement pathway)
- Lead Candidates: ANX005, ANX007
- Indication: Alzheimer's disease (potential)
- Stage: Phase 2 (HD), expanding to AD
- Mechanism: Anti-C1q monoclonal antibody
- Notes: Targets complement-mediated synaptic pruning and neuroinflammation[@annexon_corp]
Microglia Modulation
Prothelia
- Focus: TREM2 and tau targeting
- Lead Candidate: PRX005
- Indication: Alzheimer's disease
- Stage: Phase 1
- Mechanism: Anti-tau antibody with microglial modulation
- Notes: Targets both pathological tau and microglial function
Cassava Sciences
- Focus: Neuroinflammation modulation
- Lead Candidate: SavaRx
- Indication: Alzheimer's disease
- Stage: Phase 3
- Mechanism: Novel mechanism targeting neuroinflammation
- Notes: Late-stage development with potential for approval
Lundbeck
- Focus: Microglial modulation
- Lead Candidate: Lu AF20513
- Indication: Alzheimer's disease
- Stage: Phase 1
- Mechanism: Amyloid/TREM2 targeting vaccine
- Notes: Combination approach targeting both amyloid and microglia
Pipeline Overview
| Company | Drug | Mechanism | Phase | Indication |
|---------|------|-----------|-------|------------|
| Nodthera | NT-0796 | NLRP3 inhibitor | Phase 1/2 | AD |
| INmune Bio | XPro1595 | Anti-sTNFα | Phase 2 | AD (MCI) |
| Alector | AL002 | TREM2 agonist | Phase 2 | AD |
| Alector | AL101 | Progranulin | Phase 2 | AD |
| Vigil Neuroscience | VIG-100 | TREM2 agonist | Phase 1 | AD |
| Denali Therapeutics | DNL919 | TREM2 agonist | Phase 1 | AD |
| Annexon | ANX005 | C1q inhibitor | Phase 2 | HD→AD |
| Prothelia | PRX005 | Anti-tau/microglia | Phase 1 | AD |
| Cassava Sciences | SavaRx | Neuroinflammation | Phase 3 | AD |
| Olatec | Dapansutrile | NLRP3 inhibitor | Phase 2 | AD |
Mechanism of Action Summary
Neuroinflammation in Alzheimer's Disease
Chronic neuroinflammation in Alzheimer's disease involves multiple interconnected pathways:
Therapeutic Approaches
| Mechanism | Target | Companies | Development Stage |
|-----------|--------|-----------|-------------------|
| NLRP3 Inhibition | Inflammasome assembly | Nodthera, Olatec | Phase 1-2 |
| TNF-α Inhibition | Soluble TNF signaling | INmune Bio | Phase 2 |
| TREM2 Agonism | Microglial activation | Alector, Vigil, Denali | Phase 1-2 |
| Complement Inhibition | C1q-mediated pruning | Annexon | Phase 2 |
| Microglia Modulation | CSF1R, CX3CR1 | Lundbeck, Prothelia | Phase 1-3 |
Cross-Links to Related Pages
Mechanism Pages
- [Neuroinflammation in AD](/mechanisms/neuroinflammation-ad)
- [Neuroinflammation Pathway](/mechanisms/neuroinflammation-pathway)
- [TREM2 and Neuroinflammation](/proteins/trem2)
- [NLRP3 Inflammasome](/entities/nlrp3-inflammasome)
- [Complement System](/mechanisms/complement-system-neurodegeneration)
- [Microglia in Neuroinflammation](/cell-types/microglia-neuroinflammation)
Investment Pages
- [Neuroinflammation Therapeutics Investment Landscape](/investment/neuroinflammation-therapeutics)
Company Pages
- [Nodthera Ltd.](/companies/nodthera)
- [INmune Bio, Inc.](/companies/inmune-bio)
- [Alector, Inc.](/companies/alector)
- [Annexon Biosciences](/companies/annexon)
- [Vigil Neuroscience](/companies/vigil-neuroscience)
- [Denali Therapeutics](/companies/denali-therapeutics)
- [AD cGAS-STING and Innate Immune Companies](/companies/ad-cgas-sting-innate-immune-companies)
Disease Pages
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Mild Cognitive Impairment](/diseases/mild-cognitive-impairment)
Clinical Trial Landscape
| Company | Drug | NCT Number | Phase | Status |
|---------|------|------------|-------|--------|
| INmune Bio | XPro1595 | NCT05318937 | Phase 2 | Recruiting |
| Nodthera | NT-0796 | NCT05632433 | Phase 1/2 | Recruiting |
| Alector | AL002 | NCT05139056 | Phase 2 | Active |
See Also
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Neuroinflammation Mechanisms](/mechanisms/neuroinflammation)
- [Investment Landscape: Neuroinflammation](/investment/neuroinflammation-therapeutics)
- [Emerging Novel Mechanism AD Companies](/companies/emerging-novel-mechanism-ad-companies-2024-2025)
References
▸Metadataorigin_type: v1_polymorphic_backfill
| slug | companies-ad-neuroinflammation-companies |
| kg_node_id | None |
| entity_type | company |
| origin_type | v1_polymorphic_backfill |
| source_table | wiki_pages |
| wiki_page_id | wp-b8ea45ea8c4c |
| __merged_from | {'merged_at': '2026-05-13', 'unprefixed_id': 'companies-ad-neuroinflammation-companies'} |
| _schema_version | 1 |
No provenance edges found
Use ?embed=1 to load the artifact without SciDEX chrome — suitable for iframing into wiki pages or external sites.
<iframe src="http://scidex.ai/artifact/wiki-companies-ad-neuroinflammation-companies?embed=1" width="100%" height="600" style="border:0;border-radius:8px"></iframe>
[Alzheimer's Disease Neuroinflammation Companies](http://scidex.ai/artifact/wiki-companies-ad-neuroinflammation-companies)
http://scidex.ai/artifact/wiki-companies-ad-neuroinflammation-companies